Evidence map›Paper›PMID 42395613›Full record

ArticleFrontiers in pediatrics2026

Transcriptome-Inferred metabolic subtypes define prognostic and immune ecosystems in osteosarcoma at single-cell resolution.

Li Hu, Dingsheng Zhang, Boyang Wang, Qian Liu, Xingyu Liao, Feiyang Qi, Linxi Chen, Huimin Liu, Zhiqing Zhao, Haijie Liang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Li Hu *Familial & Hereditary Cancer Center, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing, China.
Dingsheng Zhang *Department of Medical Affairs, Peking University People's Hospital, Beijing, China.
Boyang Wang *Musculoskeletal Tumor Center, Beijing Key Laboratory for Musculoskeletal Tumors, Peking University People's Hospital, Beijing, China.
Qian LiuFamilial & Hereditary Cancer Center, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing, China.
Xingyu LiaoFamilial & Hereditary Cancer Center, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing, China.
Feiyang QiMusculoskeletal Tumor Center, Beijing Key Laboratory for Musculoskeletal Tumors, Peking University People's Hospital, Beijing, China.
Linxi ChenMusculoskeletal Tumor Center, Beijing Key Laboratory for Musculoskeletal Tumors, Peking University People's Hospital, Beijing, China.
Huimin LiuMultidisciplinary Diagnosis and Treatment Center for Bone Tumors, Peking University Shougang Hospital, Beijing, China.
Zhiqing ZhaoDepartment of Orthopedics, Peking University First Hospital, Beijing, China.
Haijie LiangMusculoskeletal Tumor Center, Beijing Key Laboratory for Musculoskeletal Tumors, Peking University People's Hospital, Beijing, China.
Xingyu LiuMusculoskeletal Tumor Center, Beijing Key Laboratory for Musculoskeletal Tumors, Peking University People's Hospital, Beijing, China.
Zhiye DuMusculoskeletal Tumor Center, Beijing Key Laboratory for Musculoskeletal Tumors, Peking University People's Hospital, Beijing, China.
Rui YangDepartment of Orthopedic Surgery, UTHealth McGovern Medical School, University of Texas Health Science Center, Houston, TX, United States.
Yi YangDepartment of Medical Affairs, Peking University People's Hospital, Beijing, China.
Yang WangComprehensive Clinical Trial Ward, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Jichuan WangMusculoskeletal Tumor Center, Beijing Key Laboratory for Musculoskeletal Tumors, Peking University People's Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma exhibits substantial metabolic heterogeneity, yet existing classification schemes typically rely on narrow pathway windows and lack cellular-source attribution. Here, we integrated bulk transcriptomes from 157 osteosarcoma tumors (PKUPH-OS,

Indexed as

cholesterol metabolismconsensus clusteringmetabolic subtypingosteosarcomaoxidative phosphorylationredox homeostasissingle-cell RNA sequencingtumor microenvironment

Identifiers

PMID42395613
PMCPMC13323242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.